Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3863-3870

  Chung, Yuen Li ^a   Troy, Helen ^a   Judson, Ian R ^b   Leek, Russell ^c   Leach, Martin O ^d   Stubbs, Marion ^a   Harris, Adrian L ^c   Griffiths, John R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; CYTIDINE DERIVATIVE; DOXIFLURIDINE; DRUG METABOLITE; THYMIDINE PHOSPHORYLASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER TUMOR; CANCER PATIENT; CONTROLLED STUDY; DRUG METABOLISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEASUREMENT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR MODEL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA, COMPLEMENTARY; FLUORINE; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; PHANTOMS, IMAGING; TEMPERATURE; THYMIDINE PHOSPHORYLASE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 2542521699     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0237     Document Type: Article

References (42)

1. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
2. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the effect of capecitabine and deoxyfluoridine and the ratio of thymidine phosphorylase to dehydrogenase activities in tumor in human cancer xenografts. Cancer Res 1998;58:685-90.
3. Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′ -deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995;72:669-75.
4. Marchetti S, Chazal M, Dubreuil A, Fischel JL, Etienne MC, Milano G. Impact of thymidine phosphorylase expression on fluoropyrimidine activity and on tumor angiogenesis. Br J Cancer 2001;85:439-45.
5. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-7.
6. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Pharmacokinetics 1989;16:215-37.
7. Heggie GD, Sommadossi, J-P, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987;47:2203-6.
8. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor Nature (Lond) 1989;338:557-62.
9. Miyadera K, Sumizawa T, Haraguchi M, et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995; 55:1687-90.
10. Moghaddam A, Zhang HT, Fan TPD, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:998-1002.
11. Brown NS, Bricknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998;334:1-8.
12. Matsuura T, Kuratate I, Teramachi K, Osaki M, Fukuda Y, Ito H. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis on human colorectal carcinomas. Cancer Res 1999;59:5037-40.
13. Kitazono M, Takebayashi Y, Ishitsuka K, et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253:797-803.
14. Maeda K, Chung Y-S, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996;73: 884-8.
15. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathological and prognostic significance of an angiogenic factor, thymidine phosphorylase in human colorectal carcinoma. J Natl Cancer Inst (Bethesda) 1996;88:1110-7.
16. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer (Phila) 1997;79:1190-4.
17. Reynolds K, Farzaneh F, Collins WP, et al. Correlation of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst (Bethesda) 1994;86:1234-8.
18. Imazano Y, Takebayashi Y, Nishiyama K, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570-8.
19. Kubota Y, Miura T, Moriyanna M, et al. Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin Cancer Res 1997;3:973-6.
20. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996;73:275-80.
21. O'Brien TS, Fox SB, Dickinson AJ, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996;56:4799-804.
22. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001;18:1190-202.
23. Nishimura G, Terada I, Kobayashi T, et al. Thymidine phosphorylase and dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002;9:479-82.
24. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32:333-8.
25. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.
26. Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999;83:127-34.
27. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948-53.
28. Blanquicett C, Gillespie GY, Nabors LB, et al. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 2002;1:1139-45.
29. Steven AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR. 5-Flourouracil metabolism monitored in vivo by 19F NMR. Br J Cancer 1984;50:113-7.
30. McSheehy PMJ, Lemaire LP, Griffiths JR. Fluorine-19 MRS: application in oncology. In: Grant DM, Harris RK, editors. Encyclopedia of Nuclear Magnetic Resonance, Vol 2. New York: Wiley; 1996. p. 2048-51.
31. McSheehy PMJ, Robinson SP, Ojugo ASE, et al. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxia murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res 1998; 58:1185-94.
32. McSheehy PMJ, Seymour MT, Ojugo ASE, et al. A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumors using 19F and 31P magnetic resonance spectroscopy. Eur J Cancer 1997;33: 2418-27.
33. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Prog Nuc Magn Reson Spect 1998;33:1-56.
34. Wolf W, Waluch V, Presant CA. Non-invasive 19F-MRS of 5-fluorouracil in pharmacokinetic and pharmacodynamic studies. NMR Biomed 1998;11:380-7.
35. Findlay MP, Leach MO. In vivo monitoring of fluoropyrimidine metabolites: Magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anti-Cancer Drugs 1994;5:260-80.
36. Prior MJW, Maxwell RJ, Griffiths JR. In vivo 19F NMR spectroscopy of the antimetabolite 5-fluorouracil and its analogues. Biochem Pharmacol 1990;39:857-63.
37. Maxwell RJ, Workman P, Griffiths JR. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. J Radiat Oncol Biol Phys 1988;16: 925-9.
38. Aboagye EO, Maxwell RJ, Kelson AB, et al. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl-)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res 1997;57:3314-8.
39. Blackstock AW, Lightfoot H, Case LD, et al. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 2001;7:3263-8.
40. 10-propargyl-2′ -trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F NMR spectrscopy. Br J Cancer 1990; 62:766-72.
41. Jones A, Fujiyama C, Turner K, et al. Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion. J Urol 2002;167:1482-6.
42. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia, second edition. Br J Cancer 1998;77:1-10.